COPD Trial, Recruiting NCT07030881 Sponsor: First Affiliated Hospital of Ningbo University Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT07030881
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 65 years of age or older (any gender)
  • You have been diagnosed with either COPD (a lung condition affecting breathing) or asthma, confirmed by a doctor using standard guidelines
  • You are currently using a specific type of inhaler that combines three medicines in one device (called a pMDI), and you have been on this stable treatment for at least 4 weeks
  • In the past 12 months, you have either been hospitalized at least once due to a flare-up of your lung condition, OR you have had at least 2 flare-ups that needed steroid tablets and/or antibiotics
  • You are able to learn how to use an inhaler correctly and can handle and communicate about the device
  • You are willing and able to sign a consent form agreeing to take part in the study

Who may not be able to join:

  • Your main inhaler is a different type of device, such as a dry powder inhaler, soft mist inhaler, or a nebuliser (a machine that turns medicine into a mist)
  • You have regularly used a spacer device (a tube that attaches to an inhaler) for 3 or more weeks in the 3 months before joining
  • You are currently having a flare-up of your lung condition, or had one within the last 4 weeks that has not fully cleared up
  • You have significant memory or thinking difficulties (based on a standard test score) (confirm with trial site)
  • You have a serious ongoing illness such as advanced cancer, severe heart failure, or severe liver or kidney problems
  • You are already taking part in another clinical trial that involves a treatment or intervention
  • You are unable to use a mouthpiece-style spacer device — for example, due to a physical issue with your mouth or face, or severe anxiety
  • You have a known allergy or sensitivity to the materials used in spacer devices

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-0574-87089878

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
First Affiliated Hospital of Ningbo University
Registry
ClinicalTrials.gov
Start date
17 June 2025
Est. completion
30 June 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Moderate-to-Severe Acute Exacerbations Within 3 Months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov